查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1980798

2026-2034年全球血友病治療市場規模、佔有率、趨勢和成長分析報告

Global Hemophilia Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 267 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

血友病治療市場預計將從 2025 年的 200.8 億美元成長到 2034 年的 334.6 億美元，2026 年至 2034 年的複合年成長率為 5.84%。

全球血友病治療市場正穩步成長，這主要得益於血友病診斷病例的增加以及意識提升。血友病是一種需要終身管理的遺傳性出血性疾病，因此對有效治療方法的需求持續強勁。醫療基礎設施的改善和診斷工具的普及也促進了確診患者數量的成長，從而推動了已開發經濟體和新興經濟體市場的擴張。

生物技術和藥物研發的進步顯著改善了血友病患者的治療選擇。重組凝血因子、長效製劑和非因子替代療法的引入提高了治療效果，並減少了注射次數。此外，製藥公司和研究機構加大投入，加速了旨在改善患者生活品質的創新治療方法的研發。

未來，基因療法和個人化醫療技術的快速發展可望惠及血友病治療市場。基因治療方法有望為患者提供長期或根治性的解決方案，並將徹底改變治療方式。醫療保健支出的增加和專業治療中心的可近性提高預計也將繼續推動全球市場成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球血友病治療市場：依疾病類型分類

  • 市場分析、洞察與預測
  • A型血友病A
  • B型血友病
  • 其他疾病類型

第5章 全球血友病治療市場：依產品分類

  • 市場分析、洞察與預測
  • 重組凝血因子濃縮物
  • 血漿衍生凝血因子濃縮物
  • 延長半衰期產物
  • 去氨加壓素
  • 抗纖維蛋白溶解劑
  • 基因治療產品

第6章 全球血友病治療市場：依患者類型分類

  • 市場分析、洞察與預測
  • 兒童
  • 成人

第7章 全球血友病治療市場：依治療方式分類

  • 市場分析、洞察與預測
  • 預防性治療
  • 一經請求

第8章 全球血友病治療市場：依治療方法

  • 市場分析、洞察與預測
  • 因子替代療法
  • 非因子替代療法

第9章 全球血友病治療市場：依藥物類別分類

  • 市場分析、洞察與預測
  • 增壓素
  • 凝血因子

第10章 全球血友病治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 注射藥物
  • 鼻內噴劑
  • 口服

第11章 全球血友病治療市場：依最終用途分類

  • 市場分析、洞察與預測
  • 醫院
  • 診所
  • 血友病治療中心
  • 其他最終用戶

第12章 全球血友病治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第13章 競爭格局

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第14章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Bayer AG
    • Biogen Inc
    • Biotest AG（Grifols SA）
    • BioMarin Pharmaceutical Inc
    • CSL Behring LLC
    • Ferring BV
    • Genentech Inc.（Roche Holding AG）
    • Kedrion SPA
    • Novo Nordisk A/S
    • Octapharma AG
    • Pfizer Inc
    • Sanofi SA
    • Swedish Orphan Biovitrum AB
    • Takeda Pharmaceutical Company Limited
簡介目錄
Product Code: VMR112115486

The Hemophilia Treatment Market size is expected to reach USD 33.46 Billion in 2034 from USD 20.08 Billion (2025) growing at a CAGR of 5.84% during 2026-2034.

The global hemophilia treatment market is growing steadily due to the increasing diagnosis of hemophilia and rising awareness about early treatment. Hemophilia, a genetic bleeding disorder, requires lifelong management, which has led to sustained demand for effective therapies. Improved healthcare infrastructure and greater availability of diagnostic tools have also contributed to the growing number of diagnosed patients, supporting market expansion across both developed and emerging economies.

Advancements in biotechnology and pharmaceutical research have significantly improved treatment options for hemophilia patients. The introduction of recombinant clotting factors, extended half-life therapies, and non-factor replacement therapies has enhanced treatment outcomes and reduced the frequency of injections. In addition, increasing investments by pharmaceutical companies and research institutions are accelerating the development of innovative therapies aimed at improving patient quality of life.

In the future, the hemophilia treatment market is expected to benefit from the rapid progress of gene therapy and personalized medicine approaches. Gene-based treatments have the potential to offer long-term or even curative solutions for patients, transforming the treatment landscape. Increasing healthcare expenditure and improved access to specialized treatment centers are also expected to drive continued market growth globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Disease Type

  • Hemophilia A
  • Hemophilia B
  • Other disease types

By Product

  • Recombinant coagulation factor concentrates
  • Plasma-derived coagulation factor concentrates
  • Extended half-life products
  • Desmopressin
  • Antifibrinolytic agents
  • Gene therapy products

By Patient

  • Pediatric
  • Adult

By Treatment

  • Prophylaxis
  • On demand

By Therapy

  • Factor replacement therapy
  • Non-factor replacement therapy

By Drug Class

  • Vasopressin
  • Coagulation factors

By Route of Administration

  • Injectable
  • Nasal spray
  • Oral

By End-use

  • Hospitals
  • Clinics
  • Hemophilia treatment centers
  • Other end-users

COMPANIES PROFILED

  • Bayer AG, Biogen Inc, Biotest AG Grifols, SA, BioMarin Pharmaceutical Inc, CSL Behring LLC, Ferring BV, Genentech Inc Roche Holding AG, Kedrion SpA, Novo Nordisk AS, Octapharma AG, Pfizer Inc, Sanofi SA, Swedish Orphan Biovitrum AB, Takeda Pharmaceutical Company Limited
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL HEMOPHILIA TREATMENT MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Disease Type
  • 4.2. Hemophilia A Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Hemophilia B Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Other disease types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HEMOPHILIA TREATMENT MARKET: BY PRODUCT 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Product
  • 5.2. Recombinant coagulation factor concentrates Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Plasma-derived coagulation factor concentrates Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Extended half-life products Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Desmopressin Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Antifibrinolytic agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.7. Gene therapy products Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HEMOPHILIA TREATMENT MARKET: BY PATIENT 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Patient
  • 6.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HEMOPHILIA TREATMENT MARKET: BY TREATMENT 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Treatment
  • 7.2. Prophylaxis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. On demand Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL HEMOPHILIA TREATMENT MARKET: BY THERAPY 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast Therapy
  • 8.2. Factor replacement therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Non-factor replacement therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL HEMOPHILIA TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 9.1. Market Analysis, Insights and Forecast Drug Class
  • 9.2. Vasopressin Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 9.3. Coagulation factors Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL HEMOPHILIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 10.1. Market Analysis, Insights and Forecast Route Of Administration
  • 10.2. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 10.3. Nasal spray Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 10.4. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 11. GLOBAL HEMOPHILIA TREATMENT MARKET: BY END-USE 2022-2034 (USD MN)

  • 11.1. Market Analysis, Insights and Forecast End-use
  • 11.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 11.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 11.4. Hemophilia treatment centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 11.5. Other end-users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 12. GLOBAL HEMOPHILIA TREATMENT MARKET: BY REGION 2022-2034(USD MN)

  • 12.1. Regional Outlook
  • 12.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 12.2.1 By Disease Type
    • 12.2.2 By Product
    • 12.2.3 By Patient
    • 12.2.4 By Treatment
    • 12.2.5 By Therapy
    • 12.2.6 By Drug Class
    • 12.2.7 By Route Of Administration
    • 12.2.8 By End-use
    • 12.2.9 United States
    • 12.2.10 Canada
    • 12.2.11 Mexico
  • 12.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 12.3.1 By Disease Type
    • 12.3.2 By Product
    • 12.3.3 By Patient
    • 12.3.4 By Treatment
    • 12.3.5 By Therapy
    • 12.3.6 By Drug Class
    • 12.3.7 By Route Of Administration
    • 12.3.8 By End-use
    • 12.3.9 United Kingdom
    • 12.3.10 France
    • 12.3.11 Germany
    • 12.3.12 Italy
    • 12.3.13 Russia
    • 12.3.14 Rest Of Europe
  • 12.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 12.4.1 By Disease Type
    • 12.4.2 By Product
    • 12.4.3 By Patient
    • 12.4.4 By Treatment
    • 12.4.5 By Therapy
    • 12.4.6 By Drug Class
    • 12.4.7 By Route Of Administration
    • 12.4.8 By End-use
    • 12.4.9 India
    • 12.4.10 Japan
    • 12.4.11 South Korea
    • 12.4.12 Australia
    • 12.4.13 South East Asia
    • 12.4.14 Rest Of Asia Pacific
  • 12.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 12.5.1 By Disease Type
    • 12.5.2 By Product
    • 12.5.3 By Patient
    • 12.5.4 By Treatment
    • 12.5.5 By Therapy
    • 12.5.6 By Drug Class
    • 12.5.7 By Route Of Administration
    • 12.5.8 By End-use
    • 12.5.9 Brazil
    • 12.5.10 Argentina
    • 12.5.11 Peru
    • 12.5.12 Chile
    • 12.5.13 South East Asia
    • 12.5.14 Rest of Latin America
  • 12.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 12.6.1 By Disease Type
    • 12.6.2 By Product
    • 12.6.3 By Patient
    • 12.6.4 By Treatment
    • 12.6.5 By Therapy
    • 12.6.6 By Drug Class
    • 12.6.7 By Route Of Administration
    • 12.6.8 By End-use
    • 12.6.9 Saudi Arabia
    • 12.6.10 UAE
    • 12.6.11 Israel
    • 12.6.12 South Africa
    • 12.6.13 Rest of the Middle East And Africa

Chapter 13. COMPETITIVE LANDSCAPE

  • 13.1. Recent Developments
  • 13.2. Company Categorization
  • 13.3. Supply Chain & Channel Partners (based on availability)
  • 13.4. Market Share & Positioning Analysis (based on availability)
  • 13.5. Vendor Landscape (based on availability)
  • 13.6. Strategy Mapping

Chapter 14. COMPANY PROFILES OF GLOBAL HEMOPHILIA TREATMENT INDUSTRY

  • 14.1. Top Companies Market Share Analysis
  • 14.2. Company Profiles
    • 14.2.1 Bayer AG
    • 14.2.2 Biogen Inc
    • 14.2.3 Biotest AG (Grifols S.A.)
    • 14.2.5 BioMarin Pharmaceutical Inc
    • 14.2.6 CSL Behring LLC
    • 14.2.7 Ferring B.V
    • 14.2.8 Genentech Inc. (Roche Holding AG)
    • 14.2.9 Kedrion S.P.A
    • 14.2.10 Novo Nordisk A/S
    • 14.2.11 Octapharma AG
    • 14.2.12 Pfizer Inc
    • 14.2.13 Sanofi SA
    • 14.2.14 Swedish Orphan Biovitrum AB
    • 14.2.15 Takeda Pharmaceutical Company Limited